<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Hierarchical Composite Endpoints</title>

<script src="site_libs/header-attrs-2.22/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Monitoring-of-Adaptive-Clinical-Trials.html">Design and Monitoring of Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Evaluation-of-Complex-Sequential-Trials.html">Design and Evaluation of Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Evaluation-of-Diagnostic-Study.html">Design and Evaluation of Diagnostic Study</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot_Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="05-Plot_Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
  </ul>
</li>
<li>
  <a href="07-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Hierarchical Composite Endpoints</p></h1>

</div>


<div id="multiple-endpoints" class="section level1">
<h1>Multiple Endpoints</h1>
<div id="introduction" class="section level2">
<h2>Introduction</h2>
<div id="co-primary-endpoints" class="section level3">
<h3>1. <strong>Co-primary Endpoints</strong></h3>
<ul>
<li><strong>Regulatory Expectations</strong>: A trial with co-primary
endpoints is only considered successful if <strong>all</strong>
co-primary endpoints show statistically significant effects. This
increases the risk of <strong>Type I errors</strong>, where a true
effect might be missed because the test becomes more stringent.
Therefore, careful planning around sample size and statistical power is
crucial to ensure the trial can detect significant effects across all
endpoints.</li>
<li><strong>Hypothesis/Trial Success</strong>: The null hypothesis (H₀)
assumes that none of the endpoints show any effect (θ₁ = 0 ∧ … ∧ θₖ =
0). The alternative hypothesis (Hₐ) requires that all endpoints must
show an effect (θ₁ ≠ 0 ∧ … ∧ θₖ ≠ 0) for the trial to be
successful.</li>
</ul>
</div>
<div id="endpoint-family" class="section level3">
<h3>2. <strong>Endpoint Family</strong></h3>
<ul>
<li><strong>Regulatory Expectations</strong>: When multiple primary
endpoints are grouped, regulatory authorities expect careful
<strong>management of multiplicity</strong> to control the risk of
false-positive results due to multiple testing. A <strong>family-wise
error rate control</strong> is recommended to prevent incorrect
conclusions. This often requires adjustments in statistical procedures
to ensure the results remain reliable across the multiple
endpoints.</li>
<li><strong>Hypothesis/Trial Success</strong>: Here, the null hypothesis
(H₀) still assumes no effect for all endpoints (θ₁ = 0 ∧ … ∧ θₖ = 0),
but the alternative hypothesis (Hₐ) allows the trial to be successful if
at least one endpoint shows an effect (at least one θᵢ ≠ 0, i ∈
{1,…,K}).</li>
</ul>
</div>
<div id="composite-endpoints" class="section level3">
<h3>3. <strong>Composite Endpoints</strong></h3>
<ul>
<li><strong>Regulatory Expectations</strong>: Composite endpoints
combine multiple individual outcomes into a single measure. The
treatment effects should be <strong>consistent across all
components</strong> of the composite endpoint. If one component shows a
large effect, it could dominate the overall result, which may not
accurately reflect the true treatment benefit. Therefore, each
component’s contribution to the overall effect must be carefully
examined.</li>
<li><strong>Hypothesis/Trial Success</strong>: The null hypothesis (H₀)
assumes no effect on the composite endpoint (θc = 0), while the
alternative hypothesis (Hₐ) indicates an effect on the composite
endpoint (θc ≠ 0).</li>
</ul>
</div>
<div id="multi-component-endpoints" class="section level3">
<h3>4. <strong>Multi-component Endpoints</strong></h3>
<ul>
<li><strong>Regulatory Expectations</strong>: Multi-component endpoints
evaluate several outcomes within a single endpoint to increase the
trial’s efficiency. However, discrepancies among the effects of
different components could undermine the ability to detect a significant
overall treatment effect. <strong>Validation</strong> of the endpoint is
critical to ensure it properly captures the overall treatment
benefit.</li>
<li><strong>Hypothesis/Trial Success</strong>: The null hypothesis (H₀)
assumes no overall effect (θ = 0), while the alternative hypothesis (Hₐ)
suggests there is a treatment effect (θ ≠ 0).</li>
</ul>
</div>
</div>
<div id="advantages-and-disadvantages-of-using-composite-endpoints"
class="section level2">
<h2>Advantages and disadvantages of using composite endpoints</h2>
<div id="advantages" class="section level3">
<h3>Advantages</h3>
<ol style="list-style-type: decimal">
<li><p><strong>Reduced Sample Size Requirement:</strong> Composite
endpoints allow for a smaller sample size compared to evaluating each
endpoint separately because they aggregate multiple outcomes, increasing
the likelihood of observing an event and thus enhancing the power of the
study.</p></li>
<li><p><strong>Reduced Follow-up Period:</strong> The duration of
follow-up can be shortened because an event is more likely to occur when
multiple outcomes are combined. This can lead to quicker study
conclusions and faster movement through trial phases.</p></li>
<li><p><strong>Reduced Costs:</strong> A smaller sample size and shorter
follow-up period contribute to lower overall costs. This includes fewer
resources needed for patient management, monitoring, and data
collection.</p></li>
<li><p><strong>Can Assess the Net Clinical Benefit:</strong> By
including variables of both safety and efficacy, composite endpoints can
provide a holistic view of the intervention’s net clinical benefit. This
approach reflects the balance between positive and negative outcomes,
offering a comprehensive measure of a treatment’s overall
effect.</p></li>
</ol>
</div>
<div id="disadvantages" class="section level3">
<h3>Disadvantages</h3>
<ol style="list-style-type: decimal">
<li><p><strong>Difficulty in Interpretation and Risk of Misleading
Conclusions:</strong> Composite endpoints can be complex to analyze and
interpret. If different components of the composite have varying levels
of importance or clinical impact, the overall endpoint might mask or
exaggerate the effect of the treatment.</p></li>
<li><p><strong>Components Not Explicitly Discriminated:</strong> Often,
the individual components of a composite endpoint are not analyzed
separately in depth, which can obscure which specific outcomes are
driving the overall effect. This lack of discrimination can lead to
misunderstandings about the effectiveness of the treatment for
particular aspects of patient health.</p></li>
<li><p><strong>Lack of Complete Discussion by Authors:</strong> There
might be insufficient discussion regarding the scope and implications of
the results linked to the composite endpoint. Authors might not fully
address how the composite nature of the endpoint affects the study
conclusions, leaving gaps in the understanding of the data.</p></li>
<li><p><strong>No Distinction in Clinical Significance of
Components:</strong> Traditional analysis methods for composite
endpoints treat all components as equally important, which might not
reflect their true clinical relevance. This can lead to conclusions that
do not accurately represent the value of the treatment for more
significant outcomes.</p></li>
<li><p><strong>Counts Only the First Occurrence of Any Event:</strong>
In traditional analyses, once any component of the composite endpoint
occurs, it is counted, and subsequent events are not considered. This
approach may not accurately reflect the overall burden or frequency of
health events over time, potentially underestimating the treatment’s
impact or risks.</p></li>
</ol>
</div>
</div>
<div id="win-statistics" class="section level2">
<h2>Win Statistics</h2>
<ul>
<li><strong>Win Statistics</strong>: This approach involves using all
events with considerations for both the timing and severity of each
event, providing a holistic view of the outcomes.</li>
<li><strong>Weighted Composite Endpoint Semiparametric Proportional
Rates</strong>: This model uses all events but adjusts for the different
weights (importance or impact) assigned to each type of event,
potentially providing a more nuanced analysis of the treatment
effects.</li>
<li><strong>Negative Binomial and Andersen-Gill Models</strong>: These
are typically used for count data or recurrent events, respectively,
often focusing on the frequency and timing of events.</li>
</ul>
<p><img src="02_Plots/StudyDesign/Comp_WinStatistics.png" width="75%" style="display: block; margin: auto;" /></p>
<div id="generalized-pairwise-comparisons-gpc" class="section level3">
<h3>Generalized Pairwise Comparisons (GPC)</h3>
<p>“Generalized Pairwise Comparisons (GPC),” is a statistical method
introduced by Buyse in 2010. This method builds on the idea of making
pairwise comparisons between patients in a treatment group and those in
a control group, refining previous methodologies by Finkelstein and
Schoenfeld from 1999.</p>
<p><strong>Purpose</strong>: GPC is designed to compare outcomes between
each patient in a treatment group and every patient in a control group,
one pair at a time.</p>
<p>Mathematical Representation</p>
<ul>
<li><strong>Uᵢⱼ</strong>: This is the score assigned to a pairwise
comparison between patient i from the treatment group and patient j from
the control group.
<ul>
<li><strong>1</strong> is assigned if patient i (treatment) has a more
favorable outcome than patient j (control).</li>
<li><strong>0</strong> indicates a tie between the two patients, meaning
their outcomes are equivalent.</li>
<li><strong>-1</strong> is assigned if patient j (control) has a more
favorable outcome than patient i (treatment).</li>
</ul></li>
<li><strong>i = 1, 2, …, Nₜ</strong> where Nₜ is the total number of
patients in the treatment group.</li>
<li><strong>j = 1, 2, …, Nc</strong> where Nc is the total number of
patients in the control group.</li>
</ul>
<p><strong>Procedure for Comparison</strong></p>
<ul>
<li><strong>Starting Point</strong>: Each comparison starts with the
most critical outcome. This could be a primary endpoint like survival or
disease progression.</li>
<li><strong>Priority of Outcomes</strong>: If the most critical outcome
results in a tie between the two patients, the comparison moves to the
next most critical outcome.</li>
<li><strong>Handling Ties</strong>: If all compared outcomes result in a
tie, the overall comparison remains a tie. This ensures that the
comparisons are comprehensive and that outcomes of lower priority do not
disproportionately influence the overall comparison.</li>
</ul>
<p><strong>Importance</strong> - <strong>Clinical Trials</strong>: GPC
is particularly useful in clinical trials where multiple outcomes are
considered, and it is essential to assess which treatment is more
effective across a range of criteria. - <strong>Statistical
Analysis</strong>: This method provides a structured approach to
statistically differentiate between treatment and control groups based
on multiple, prioritized outcomes.</p>
<p><img src="02_Plots/StudyDesign/Comp_GPC.png" width="75%" style="display: block; margin: auto;" /></p>
<ul>
<li>Treatment Win</li>
<li>Treatment Win</li>
<li>Control Win</li>
</ul>
</div>
<div id="win-ratios-win-odds-and-net-benefit" class="section level3">
<h3>win ratios, win odds, and net benefit</h3>
<p><strong>Definitions of Terms</strong> - <strong>πₜ</strong>:
Probability that a treatment patient ‘wins’ in a comparison. -
<strong>πₜₑ</strong>: Probability that a control patient ‘wins’ in a
comparison. - <strong>πₜᵢₑ</strong>: Probability of a tie between a
treatment and a control patient.</p>
<p>The total of these probabilities (πₜ + πₜₑ + πₜᵢₑ) equals 1.</p>
<p><strong>Win Ratio (WR)</strong> - <strong>Formula</strong>: WR = πₜ /
πₜₑ - <strong>Interpretation</strong>: The win ratio is the ratio of the
probability that a treatment patient wins to the probability that a
control patient wins. This ratio gives a sense of how much more likely
treatment patients are to have better outcomes compared to control
patients.</p>
<p><strong>Win Odds (WO)</strong> - <strong>Formula</strong>: - WO = (πₜ
+ 0.5πₜᵢₑ) / (πₜₑ + 0.5πₜᵢₑ) - This can be rewritten as: WO = (πₜ +
0.5(1 - πₜ - πₜₑ)) / (πₜₑ + 0.5(1 - πₜ - πₜₑ)) - Which simplifies to: WO
= (πₜ + 0.5(1 - πₜ - πₜₑ)) / (1 - [πₜ + 0.5(1 - πₜ - πₜₑ)]) -
<strong>Interpretation</strong>: The win odds adjust the simple win
ratio by considering ties as half-wins for both groups. This approach
provides a balanced view that accounts for situations where neither
group clearly outperforms the other.</p>
<p><strong>Net Benefit (NB)</strong> - <strong>Formula</strong>: NB = πₜ
- πₜₑ - <strong>Interpretation</strong>: The net benefit is the
difference in probability of winning between the treatment and control
groups. It quantifies the absolute advantage in terms of effectiveness
that the treatment group has over the control group.</p>
<p><strong>Practical Usage</strong> - <strong>Context</strong>: These
metrics are particularly useful in clinical trials where multiple
outcomes are considered, and outcomes have different weights or
priorities. - <strong>Advantages</strong>: They provide a more nuanced
assessment of treatment efficacy, especially in settings where outcomes
are not strictly binary and where ties can frequently occur. -
<strong>Framework</strong>: This method extends the traditional
Mann-Whitney odds, allowing for a structured comparison that prioritizes
outcomes based on clinical importance.</p>
<p>The reference to Dong et al. [2020a] suggests that these concepts
have been discussed in recent literature, offering a modern perspective
on analyzing clinical trials data within a framework that prioritizes
different aspects of patient outcomes. This method is particularly
useful for complex clinical scenarios where a simple comparison of
outcomes does not sufficiently capture the differences between treatment
options.</p>
</div>
<div id="variance-estimation-for-logwr-logwo-and-nb"
class="section level3">
<h3>Variance Estimation for Log(WR), Log(WO), and NB:</h3>
<ol style="list-style-type: decimal">
<li><strong>Asymptotic Variances Under Null Hypothesis</strong>:
<ul>
<li>The variances for log-transformed WR, WO, and the NB are crucial for
hypothesis testing in clinical trials. These variances help determine if
observed differences in treatment effectiveness are statistically
significant.</li>
</ul></li>
<li><strong>Formulas</strong>:
<ul>
<li><p><strong>Variance of log(WR)</strong> (<span
class="math inline">\(\hat{\sigma}^2_{\log(WR)}\)</span>): <span
class="math display">\[
\hat{\sigma}^2_{\log(WR)} = \frac{\hat{\sigma}^2_t - 2\hat{\sigma}_{tc}
+ \hat{\sigma}^2_c}{[(N_t + N_c) / 2]^2}
\]</span> Where <span class="math inline">\(\hat{\sigma}^2_t\)</span>
and <span class="math inline">\(\hat{\sigma}^2_c\)</span> are the
variances of the treatment and control outcomes, respectively, and <span
class="math inline">\(\hat{\sigma}_{tc}\)</span> is the covariance
between the treatment and control outcomes.</p></li>
<li><p><strong>Variance of log(WO)</strong> (<span
class="math inline">\(\hat{\sigma}^2_{\log(WO)}\)</span>): <span
class="math display">\[
\hat{\sigma}^2_{\log(WO)} = \frac{\hat{\sigma}^2_t - 2\hat{\sigma}_{tc}
+ \hat{\sigma}^2_c}{(N_t N_c / 2)^2}
\]</span> This formula modifies the denominator to account for the
sample sizes of both the treatment and control groups individually
rather than their combined average.</p></li>
<li><p><strong>Variance of NB</strong> (<span
class="math inline">\(\hat{\sigma}^2_{NB}\)</span>): <span
class="math display">\[
\hat{\sigma}^2_{NB} = \frac{\hat{\sigma}^2_t - 2\hat{\sigma}_{tc} +
\hat{\sigma}^2_c}{(N_t N_c)^2}
\]</span> The formula for NB variance closely aligns with that of
log(WO) but adjusts the denominator to directly reflect the product of
the sample sizes, emphasizing the interaction between the two
groups.</p></li>
</ul></li>
<li><strong>Interpretation</strong>:
<ul>
<li>These variance formulas allow researchers to quantify the
uncertainty or the variability associated with the log-transformed
ratios and differences between treatment and control groups under the
assumption that no true difference exists (null hypothesis). They are
essential for constructing confidence intervals and conducting
significance tests.</li>
</ul></li>
<li><strong>Plug-in Estimators</strong>:
<ul>
<li>The plug-in estimators for <span
class="math inline">\(\hat{\sigma}^2_t\)</span>, <span
class="math inline">\(\hat{\sigma}_{tc}\)</span>, and <span
class="math inline">\(\hat{\sigma}^2_c\)</span> are required to compute
these variances. Detailed methodologies and examples for calculating
these estimators can be found in the referenced Dong et al. [2016]
publication, which likely provides the statistical underpinnings and
proofs for these estimators.</li>
</ul></li>
</ol>
</div>
<div id="point-estimates" class="section level3">
<h3>Point Estimates</h3>
<p>Explains the mathematical relationships among three win statistics:
Net Benefit (NB), Win Odds (WO), and Win Ratio (WR). These statistics
are commonly used in clinical trials to compare two groups—typically a
treatment group and a control group.</p>
<ol style="list-style-type: decimal">
<li><strong>Net Benefit (NB) as a Function of Win Ratio (WR):</strong>
<ul>
<li><strong>Formula</strong>: <span class="math inline">\(NB = \frac{WR
- 1}{WR + 1 - P_{tie}}\)</span></li>
<li><strong>Interpretation</strong>: This formula calculates the net
benefit of a treatment over control, adjusting for the probability of a
tie (<span class="math inline">\(P_{tie}\)</span>). It scales the win
ratio by adjusting for ties, thus providing a balanced measure of net
benefit that accounts for non-differential outcomes.</li>
</ul></li>
<li><strong>Net Benefit (NB) as a Function of Win Odds (WO):</strong>
<ul>
<li><strong>Formula</strong>: <span class="math inline">\(NB = \frac{WO
- 1}{WO + 1}\)</span></li>
<li><strong>Interpretation</strong>: This relationship demonstrates that
net benefit can also be directly derived from win odds by a simple
transformation, emphasizing how changes in win odds reflect on net
benefit.</li>
</ul></li>
<li><strong>Win Odds (WO) as a Function of Net Benefit (NB):</strong>
<ul>
<li><strong>Formula</strong>: <span class="math inline">\(WO = \frac{1 +
NB}{1 - NB}\)</span></li>
<li><strong>Interpretation</strong>: This inverse relationship shows how
win odds can be expressed in terms of net benefit. As net benefit
increases, win odds increase exponentially, indicating a greater
likelihood of a favorable outcome in the treatment group compared to the
control group.</li>
</ul></li>
<li><strong>Win Odds (WO) as a Function of Win Ratio (WR) and
Probability of a Tie:</strong>
<ul>
<li><strong>Formula</strong>: <span class="math inline">\(WO = \frac{WR
- 0.5 P_{tie} (WR - 1)}{1 + 0.5 P_{tie} (WR - 1)}\)</span></li>
<li><strong>Interpretation</strong>: This formula adjusts the win ratio
for the effect of ties, thereby providing a more nuanced view of win
odds when ties are a significant factor in the trial data.</li>
</ul></li>
</ol>
</div>
</div>
</div>
<div id="source" class="section level1">
<h1>Source</h1>
<p>Project Optimus, Dose Escalation and Stratification Designs in Early
Oncology Development</p>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
